At the Royal College of Physicians on Thursday 27th July, Sanofi held an event focused on the state of UK life sciences and what can be done at this critical moment in time.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh